Senexin B

SKU: orb1298941

Description

Senexin B is a potent, selective small-molecule inhibitor of CDK8 and CDK19, exhibiting dissociation constants (Kds) of 140 nM and 80 nM, respectively. It is a valuable research tool for studying the Mediator complex in oncology and inflammation, with utility in both cellular and in vivo models of cancer.

Research Area

Cell Biology

Key Properties

• CAS Number: 1449228-40-3
• MW: 450.53
• Purity: 99.63% (May vary between batches)
• Formula: C₂₇H₂₆N₆O
• SMILES: CN1CCN(CC1)C(=O)c1ccc2cc(CCNc3ncnc4ccc(cc34)C#N)ccc2c1
• Target: CDK
• Solubility: DMSO:6 mg/mL (13.32 mM)

Bioactivity

• Target IC50:
  CDK8:140 nM (Kd)|CDK19:80 nM (Kd)
• In Vivo:
  In a spleen-to-liver colon cancer metastasis model of syngeneic mouse CT26 tumors, Senexin B treatment of mice had the same effect as CDK8 knockdown in tumor cells: suppression of metastatic growth in the liver without a significant effect on primary tumor growth in the spleen.
• In Vitro:
  Senexin B effectively inhibits CDK8/19 at low nanomolar concentrations.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

CDK19, CDK8, Senexin B

Compound Identifiers

PubChem CID

71661259